A Spanish Human Proteome Project (sHPP)
La Cristalera, Miraflores de la Sierra, Madrid, August 28-29th, 2012
Juan P Albar, ProteoRed-ISCIII, CNB-CSIC
A SPANISH HUMAN PROTEOME PROJECT (SHPP)Preliminary proposal
Index1.Introduction
International context Chromosome/gene centric approach The HPP technological pillars Protein annotation and database compilation
•The Spanish Participation in the Human Proteome Project•General and Specific Aims
General aims Specific aims
•Members of the Spanish Consortium Description of the groups ProteoRed presence in the Spanish consortium
•Working Plan Work package list Work package description
•Financing•Spanish Consortium Structure•Benefit for Spain
Spanish HPP Consortium: Current Developments on the
Characterization of the Proteins Encoded by the Chromosome 16"
5th C-HPP Consortium WorkshopThe Chromosome-Centric Human Proteome Project
May 5, 2012, Beijing
Juan-Pablo Albar (Chair)Francisco Blanco (Co-Chair)Fernando Corrales (Co-Chair)
A Spanish Human Proteome Project (sHPP)Preliminary proposal
San Sebastian, July 9th, 2012
Juan P Albar, ProteoRed-ISCIII, CNB-CSIC
The Human Proteome Project Launch
Sydney HUPO2010 23 September 2010
Geneva HUPO201112 September 2011
Sydney September 23 Human Proteome Project
The Mission of the HPP
HPP will deliver a comprehensive map of the human proteins in their biological context. HPP will provide tools for the scientific community that will allow each scientist to design experiments in a better way, as the Human Genome Project did. HPP will inspire, beyond the scientific community, other stakeholders for diagnosis, prevention, therapy and cure of diseases and improved health worldwide.
Sydney September 23 Human Proteome Project
A gene-centric proteome project
Map the human proteins (gene by gene):
• Molecular (isoforms)
• Sub-cellular (localization)
• Cells, tissues and organs (expression)
• Interaction networks
• Plasma/serum (abundance)
Use all available technology platforms:
• Mass spectrometry
• Antibodies (immunotechnologies)
• Gene fusions (GFP)
Sydney September 23 Human Proteome Project
C-HPP teams by April 24th, 2012. The C-HPP Consortium internal information
HPP technologic pillars
Legrain et al. MCP 2011
Flow of the overall procedures of the C-HPP work
Spanish HPP Consortium: Current Developments on the
Characterization of the Proteins Encoded by the Chromosome 16"
5th C-HPP Consortium WorkshopThe Chromosome-Centric Human Proteome Project
May 5, 2012, Beijing
Juan-Pablo Albar (Chair)Francisco Blanco (Co-Chair)Fernando Corrales (Co-Chair)
Chromosome 16
1.Bioinformatic analysis of chromosome 16.2.Cell type(s) selection. Trascriptomic and proteomic detailed analysis.3.Expression, purification and characterization of proteins encoded by chromosome 16 that have not been described so far.4.Development of MRM methods for the quantification of the most abundant protein species encoded by each of the chromosome 16 genes.5.Identification, characterization and quantification of protein variants from chromosome 16 genes.6.Definition of SOP7.Development of bioinformatic environment.8.Biobanking.9.Configuration of the B-D pilar for the Spanish HPP consortium.
Chromosome 16 general aims
Top 15 Biofunctions represented in chromosome 16. IPA analysis
Genes on Chromosome 16
More than 85 % of protein coding genes of chromosome 16 are expressed in lymphoid cells, epitelial cells and fibroblasts.
OMIM
NEURODEGENERATIVENEURODEGENERATIVE
CANCERCANCER
OBESITYOBESITY
AUTOINMUNE DISEASESMetabolismMitochondriaInflammation
Diseases mapping on Chromosome 16
External repositoriesExternal repositories
Development of bioinformatic environment:Spanish HPP will join the different resources to provide an unique enquiring system
PAtlasPAtlasNProtNProt
GPMDBGPMDB
PRIDEPRIDE
UProtUProtUpcomingUpcoming
Proteomics results
Proteomics results
Data standards submission
(ProteomeXchange)
Data standards submission
(ProteomeXchange)+ +EmsemblEmsembl
• Characterize the transcriptome to define the actual chr16’s gen set expressed and most importantly which genes are not expressed in the three selected cell types.
• Characterize the proteome in detail. • Expression, purification, and characterization of 22 unknown proteins available in NAPPA
collection.• Development of SRM quantitative assays.
Proteins (862) will be distributed in known (562) and unknown groups (300) and the study will be performed along 3 years, starting in 2012 (214 proteins).
Protein packs will be assigned to each of the 8 MRM groups (24), including equal proportion of known (20, with different range of theoretical difficulty) and unknown proteins (4).
Unknown proteins will be first searched by targeted discovery (TD) and relevant information resulting from this studies will be used to design MRM assays. TD groups (9) will analyze 54 proteins the first year.
Each group will use the master sample (this might require the use of synthetic peptides during the refinement steps). TD will be done in all three selected cell lines. Regarding MRM, a pool of the three cell lines will be used for the 20 known proteins. Decision on using a pool or a particular cell line for the unknown proteins will be taken in light of the results from TD.
Once developed, the assays will be validated by 2 additional groups. Finally, the quantitative assay will be set up using heavy peptides.
• Definition of Bioinformatic standards and SOPs.• Definition of Biobanking strategy, standards... in collaboration with the Spanish Biobanking
Platform.
Workplan proposal
2015 2016 2017
Biobanking
Validation of MRM assays (3 groups, immunoreagents, correlation with gene expression)
Clinical samples. Disease-related changes on protein abundance. Biomarkers
Bioinfirmatic study
MRM for 204 proteins MRM for 329 proteins
SOP, bioinformatic procedures, formats, data banks, etc.
2012 2013 2014
Biobanking
MRM for 329 proteins
Validation of MRM assays (3 groups, immunoreagents, correlation with gene expression)
Clinical samples. Disease-related changes on protein abundance. Biomarkers
Chromosome 16 timeline
Transcriptomic study
Master sample
Targeted discovery (300 proteins)
SHPP-16
PlatformC-HPP
PlatformBD-HPP
Proteo-Red/ISCIII
111 Unknow Proteins
735 Know Proteins
BiologyCells/Tissues
Diseases: PathogenesisDiagnosticPrognosisTreatment
BIOBANK/ISCIII
Who we are
• ProteoRed organization has played an active role in the HUPO-PSI activities, always in close relation with the developments and reviews of different MIAPE modules.
• ProteoRed, an initiative for the coordination, integration and development of 20 proteomics facilities placed all over Spain.
http://www.proteored.org
• ProteoRed use to organize and participate in multi-centric studies that aims to evaluate the robustness and reproducibility of different proteomics workflows.
Node 2J. Mato - CIC-bioGUNE
F. Corrales – CIMAJM. Arizmendi - UPV
Central StructureJP. Albar - CNB
J. Mato - CIC-bioGUNEJ. Abian - LP-CSIC/UAB
Assoc. to Node 1I. Casal - CIB
Assoc. To Node 5P. Carrasco - UV
Node 5M. Sánchez del Pino – CIPF
R. Bru - UA
Node6JA. Bárcena - UCO
Node 1JP. Albar - CNB
C. Gil - PCM-UCMA. Marina - CBMSO
Node 4X. Bustelo - CIC
Node 3J. Abian - LP-CSIC/UAB
J. Arribas - HUVHS. Martínez - PCBD. Andreu - UPF
FX. Avilés - IBB UABO. Bachs - UB
*
.
*
-
Assoc. to node 4F.J. Blanco - INIBIC
PortugalAna Coelho - ITQB
Deborah Penque - ProCura
Geneva Jean Charles Sanchez - UG
Geographical organizationGeographical organization
BD-HPP PlatformCoordinator: Francisco J. Blanco
Clinical ResearchBiomarkers (D/P/P/T)
1st Phase: Known Proteins2nd Phase: Unknown Proteins
Cancer Chair:Co-Chair: I. Casal)
Cancer Chair:Co-Chair: I. Casal)
CAIBER/ISCIII
Neurologic DisordersChair: A. Lopez- MunainCo-chair:JM Arizmendi
Rheumatic Diseases: Chair: FJ. BlancoCo-Chair: JP Albar
Rheumatic Diseases: Chair: FJ. BlancoCo-Chair: JP Albar
Obesity Chair: J PrietoCo-Chair: F. Corrales
Obesity Chair: J PrietoCo-Chair: F. Corrales
RETIC of Cancer
CIBERNed RETIC of Rheumatic
CIBER-Obesity
BIOBANK/ISCIII
SHPP-16
Cardiovascular Diseases: Chair: L Rodriguez-PadialCo-Chair: F. Vivanco
Cardiovascular Diseases: Chair: L Rodriguez-PadialCo-Chair: F. Vivanco
RETIC-Cardiov.
Infectiious Diseases: Chair: J FortunCo-Chair: C. Gil
Infectiious Diseases: Chair: J FortunCo-Chair: C. Gil
HOSPITALESHOSPITALES INSTITUTOS DE INVESTIGACIÓNINSTITUTOS DE INVESTIGACIÓN
CENTROS DE INVESTIGACIÓN
CENTROS DE INVESTIGACIÓN
REDES COOPERATIVAS
REDES COOPERATIVAS
CANCERDrs C. BELDA & I.
CASAL
CANCERDrs C. BELDA & I.
CASAL
Chr16-HPP Proteomics Platforms
Chr16-HPP Proteomics Platforms
NEUROLOGICAL DISEASES
Dr A. LOPEZ DE MUNAIN
NEUROLOGICAL DISEASES
Dr A. LOPEZ DE MUNAIN
CARDIOVASCULAR DISEASES
Dr F. VIVANCO & JLR: PADIAL
CARDIOVASCULAR DISEASES
Dr F. VIVANCO & JLR: PADIAL
RHEUMATIC & MUSCLOSKELETAL
DISEASESDr. F. BLANCO
RHEUMATIC & MUSCLOSKELETAL
DISEASESDr. F. BLANCO
SPANISH NATIONAL BIOBANK NETWORK-ISCIII
Dr M. MORENTE
SPANISH NATIONAL BIOBANK NETWORK-ISCIII
Dr M. MORENTE
INFECTIOUS DISEASESDrs C. GIL & J. FORTÚNINFECTIOUS DISEASESDrs C. GIL & J. FORTÚN
OBESITY/LIVER DISEASES
Drs J. PRIETO & F. CORRALES
OBESITY/LIVER DISEASES
Drs J. PRIETO & F. CORRALES
HOSPITALESHOSPITALES INSTITUTOS DE INVESTIGACIÓNINSTITUTOS DE INVESTIGACIÓN
CENTROS DE INVESTIGACIÓN
CENTROS DE INVESTIGACIÓN
REDES COOPERATIVAS
REDES COOPERATIVAS
ASOCIACIONES DE PACIENTESASOCIACIONES DE PACIENTES
MINISTERIO DE INDUSTRIA
MINISTERIO DE INDUSTRIA
MINISTERIO DE ECONOMIA Y
COMPETITIVIDAD
MINISTERIO DE ECONOMIA Y
COMPETITIVIDAD
MINISTERIO DE SANIDADMINISTERIO DE SANIDAD
MINISTERIO DE EDUCACIÓN
MINISTERIO DE EDUCACIÓN
FARMAINDUSTRIAFARMAINDUSTRIA
ASEBIOASEBIO
INVERSIÓN PRIVADA
INVERSIÓN PRIVADA
PLATAFORMAS PROTEÓMICASPLATAFORMAS PROTEÓMICAS
HPPHPP
COMUNIDADES AUTÓNOMAS
COMUNIDADES AUTÓNOMAS
EMPRESAS AFINES
EMPRESAS AFINES
Steering CommitteeSteering Committee
Analytical (C-HPP)Gene/chromosome centricAnalytical (C-HPP)Gene/chromosome centric
B-D initiativesDisease centric
B-D initiativesDisease centricBioinformaticsBioinformatics
MS and Ab based quantitative
methodsOpen access repositories
MS and Ab based quantitative
methodsOpen access repositories
Hallmarks of diseasePotential biomarkers and
therapeutic targets
Hallmarks of diseasePotential biomarkers and
therapeutic targets
Clinical devicesClinical devices
Personalized medicinePersonalized medicine
Design of prototypesQuantitation of target proteinsDesign of prototypesQuantitation of target proteins
MINECOMINECO
PharmasPharmasISCIIIISCIII
BiotechsBiotechs
MINECOMINECO ISCIIIISCIII
CNBUCMCIBFJDCicBioguneCIMACIPFUABPCBVall D’HebronUSALLa PazINIVIC
CNBUCMCIBFJDCicBioguneCIMACIPFUABPCBVall D’HebronUSALLa PazINIVIC
Board of DirectorsBoard of Directors
Project ManagerProject Manager
Technical DirectorTechnical Director Finance DirectorFinance Director
WG 1WG 1
RU1a/1bRU1a/1b
WG 4WG 4
RU 2a/2hRU 2a/2h
Working Groups
Research Units
WG 2WG 2 WG 3WG 3 WG 5WG 5
Executive Committee
RU 3a/3gRU 3a/3g RU 4a/4eRU 4a/4e RU 5a/5gRU 5a/5g
CHROMOSOME-16 CONSORTIUM STRUCTURE
WG 1.-Protein Micro Array & Peptide Standard Team
WG 1.-Protein Micro Array & Peptide Standard Team
RU1a (Protein Micro Array and Protein Expression
Team)
Dr. Manuel FuentesCIC/IBMCC (USAL/CSIC), Salamanca
RU1a (Protein Micro Array and Protein Expression
Team)
Dr. Manuel FuentesCIC/IBMCC (USAL/CSIC), Salamanca
RU1b(Peptide Standard Team)
Dr. Juan P AlbarCNB-CSIC, ProteoRed, Madrid
RU1b(Peptide Standard Team)
Dr. Juan P AlbarCNB-CSIC, ProteoRed, Madrid
Scientific Researchers:Scientific Researchers: Scientific Researchers:F. RoncalM. Lombardía
Scientific Researchers:F. RoncalM. Lombardía
WG 2.-S/MRM-Protein Platform Team WG 2.-S/MRM-Protein Platform Team
RU2aDr. Juan P. AlbarCNB-CSIC, ProteoRed, Madrid
RU2aDr. Juan P. AlbarCNB-CSIC, ProteoRed, Madrid
RU2bDr. Fernando CorralesCIMA-UN ProteoRed, Pamplona
RU2bDr. Fernando CorralesCIMA-UN ProteoRed, Pamplona
RU2cDr. Francesc CanalsV.H.I.O.ProteoRed, Barcelona
RU2cDr. Francesc CanalsV.H.I.O.ProteoRed, Barcelona
RU2dDr. Concha GilPCM-UCMProteoRed, Madrid
RU2dDr. Concha GilPCM-UCMProteoRed, Madrid
RU2e Dr. Manuel Sanchez del PinoUVProteoRed, Valencia
RU2e Dr. Manuel Sanchez del PinoUVProteoRed, Valencia
RU2fDr. Fernando Vivanco / Dr. M.E BarderasFJD,Madrid/HNP, Toledo
RU2fDr. Fernando Vivanco / Dr. M.E BarderasFJD,Madrid/HNP, Toledo
RU2gDr. Francisco BlancoINIBIC, ProteoRed, La Coruña
RU2gDr. Francisco BlancoINIBIC, ProteoRed, La Coruña
RU2hDr. Silvia BarcelóIACS, Zaragoza (Provisional)
RU2hDr. Silvia BarcelóIACS, Zaragoza (Provisional)
Scientific Researchers:M. MarcillaS. GharbiA.AlpízarC. González
Scientific Researchers:M. MarcillaS. GharbiA.AlpízarC. González
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers:
WG 3.-Protein Sequencing TeamWG 3.-Protein Sequencing Team
RU3fDr. Jesus M. ArizmendiUPVProteoRed, Bilbao
RU3fDr. Jesus M. ArizmendiUPVProteoRed, Bilbao
RU3eDr. Ignacio CasalCIB-CSIC, ProteoRed, Madrid
RU3eDr. Ignacio CasalCIB-CSIC, ProteoRed, Madrid
RU3dDr. Eliandre de OliveiraPCB, ProteoRed, Barcelona
RU3dDr. Eliandre de OliveiraPCB, ProteoRed, Barcelona
RU3cDr. Manuel Sanchez del PinoUV, ProteoRed, Valencia
RU3cDr. Manuel Sanchez del PinoUV, ProteoRed, Valencia
RU3bDr. Joaquin AbianIIBB-CSIC ProteoRed, Barcelona
RU3bDr. Joaquin AbianIIBB-CSIC ProteoRed, Barcelona
RU3aDr. José M. Mato / Dr. Félix ElortzaCIC-BioGUNE, ProteoRed, Bilbao
RU3aDr. José M. Mato / Dr. Félix ElortzaCIC-BioGUNE, ProteoRed, Bilbao
RU3gDr. Juan P. AlbarCNB-CSIC, ProteoRed, Madrid
RU3gDr. Juan P. AlbarCNB-CSIC, ProteoRed, Madrid
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers:
Scientific Researchers:A.ParadelaR. Navajas
Scientific Researchers:A.ParadelaR. Navajas
Scientific Researchers:Scientific Researchers:
WG 4.-Bioinformatics TeamWG 4.-Bioinformatics Team
RU4aDr. Juan P AlbarCNB-CSIC, ProteoRed, Madrid
RU4aDr. Juan P AlbarCNB-CSIC, ProteoRed, Madrid
RU4bDr. Fernando CorralesCIMA-UNProteoRed, Pamplona
RU4bDr. Fernando CorralesCIMA-UNProteoRed, Pamplona
RU4cDr. Joaquin AbianIIBB-CSIC ProteoRed, Barcelona
RU4cDr. Joaquin AbianIIBB-CSIC ProteoRed, Barcelona
RU4eDr. Jesus M. ArizmendiUPVProteoRed, Bilbao
RU4eDr. Jesus M. ArizmendiUPVProteoRed, Bilbao
RU4dDr. Concha GilPCM-UCMProteoRed, Madrid
RU4dDr. Concha GilPCM-UCMProteoRed, Madrid
Scientific Researchers:A.MedinaS. M-Bartolomé
Scientific Researchers:A.MedinaS. M-Bartolomé
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers:
WG 5.-Clinical Health Care & Biobanking Team (S_B/D-HPP)
WG 5.-Clinical Health Care & Biobanking Team (S_B/D-HPP)
RU5gDr. Manuel MorenteSNBN, CNIO, Madrid(considered for inclusion in the consortium)
RU5gDr. Manuel MorenteSNBN, CNIO, Madrid(considered for inclusion in the consortium)
RU5dDr. Adolfo López de MunainInst. BiodonostiaS. Sebastian
RU5dDr. Adolfo López de MunainInst. BiodonostiaS. Sebastian
RU5cDr. Rodríguez Padial/ Dr. Fernando Vivanco / Dr. M.E BarderasFJD, Madrid/HNP, Toledo
RU5cDr. Rodríguez Padial/ Dr. Fernando Vivanco / Dr. M.E BarderasFJD, Madrid/HNP, Toledo
RU5bDr. Cristobal BeldaFSB, La Paz Hospital, Madrid (Provisional)
RU5bDr. Cristobal BeldaFSB, La Paz Hospital, Madrid (Provisional)
RU5aDr. Francisco BlancoINIBIC, ProteoRed, La Coruña
RU5aDr. Francisco BlancoINIBIC, ProteoRed, La Coruña
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers:
Scientific Researchers:Scientific Researchers: Scientific
Researchers:Scientific Researchers:
RU5fDr. Concha GilPCM-UCMProteoRed, Madrid
RU5fDr. Concha GilPCM-UCMProteoRed, Madrid
RU5eDr. Fernando CorralesCIMA-UN ProteoRed, Pamplona
RU5eDr. Fernando CorralesCIMA-UN ProteoRed, Pamplona
Scientific Researchers:Scientific Researchers: Scientific
Researchers:Scientific Researchers:
WG5-Clinical Health Care & Biobanking TeamRU5a-Dr. Francisco BlancoInstituto de Investigacion Biomedica (INIBIC), ProteoRed, La CoruñaRU5b-Dr. Cristobal Belda (Provisional)Severiano Ballesteros FoundationLa Paz Hospital, MadridRU5c-Dr. Rodriguez Padial/Dr. Fernando Vivanco/ Dr. ME BarderasJimenez Díaz Foundation (FJD), Madrid /National Paraplegics Hospital, ToledoRu5d-Dr. Adolfo López de MunainInstituto Biodonostia, San SebastianRU5e-Dr. Fernando Corrales/J. PrietoCIMA-University of Navarra RU5f-Dr. Concha GilPCM-Computensis University (PCM-UCM), ProteoRed, MadridRU5g-Dr. Manuel Morente (considered for inclusion in the consortium)Spanish National BioBanking NetworkCNIO, Madrid
WG5-Clinical Health Care & Biobanking TeamRU5a-Dr. Francisco BlancoInstituto de Investigacion Biomedica (INIBIC), ProteoRed, La CoruñaRU5b-Dr. Cristobal Belda (Provisional)Severiano Ballesteros FoundationLa Paz Hospital, MadridRU5c-Dr. Rodriguez Padial/Dr. Fernando Vivanco/ Dr. ME BarderasJimenez Díaz Foundation (FJD), Madrid /National Paraplegics Hospital, ToledoRu5d-Dr. Adolfo López de MunainInstituto Biodonostia, San SebastianRU5e-Dr. Fernando Corrales/J. PrietoCIMA-University of Navarra RU5f-Dr. Concha GilPCM-Computensis University (PCM-UCM), ProteoRed, MadridRU5g-Dr. Manuel Morente (considered for inclusion in the consortium)Spanish National BioBanking NetworkCNIO, Madrid
WG4-Bioinformatics TeamRU4a-Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, MadridRU4b-Dr. Fernando CorralesCIMA-University of Navarra ProteoRed, PamplonaRU4c-Dr. Joaquin AbianIIBB, CSIC, ProteoRed, BarcelonaRU4d-Dr. Concha GilPCM-Computensis University (PCM-UCM), ProteoRed, MadridRU4e-Dr. Jesus M. ArizmendiBasque Country University, ProteoRed, Bilbao
WG4-Bioinformatics TeamRU4a-Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, MadridRU4b-Dr. Fernando CorralesCIMA-University of Navarra ProteoRed, PamplonaRU4c-Dr. Joaquin AbianIIBB, CSIC, ProteoRed, BarcelonaRU4d-Dr. Concha GilPCM-Computensis University (PCM-UCM), ProteoRed, MadridRU4e-Dr. Jesus M. ArizmendiBasque Country University, ProteoRed, Bilbao
WG2-S/MRM-Protein Platform TeamRU2a-Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, MadridRU2b-Dr. Fernando CorralesCIMA-University of Navarra, ProteoRed, PamplonaRU2c-Dr. Francesc CanalsVall d'Hebron Institut d'Oncologia (V.H.I.O.),ProteoRed, BarcelonaRU2d-Dr. Concha GilMadrid Science Park-Computensis University (PCM-UCM), ProteoRed, MadridRU2e-Dr. Manuel Sanchez del PinoFelipe Princess Research Center (CIPF), ProteoRed, ValenciaRU2f-Dr. Fernando Vivanco / Dr. ME BarderasJimenez Díaz Foundation (FJD), Madrid /National Paraplegics Hospital, ToledoRU2g-Dr. Francisco BlancoInstituto de Investigacion Biomedica (INIBIC), ProteoRed, La CoruñaRU2h-Dr Silvia BarcelóAragón Health Sciences Institute (IACS), Zaragoza
WG2-S/MRM-Protein Platform TeamRU2a-Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, MadridRU2b-Dr. Fernando CorralesCIMA-University of Navarra, ProteoRed, PamplonaRU2c-Dr. Francesc CanalsVall d'Hebron Institut d'Oncologia (V.H.I.O.),ProteoRed, BarcelonaRU2d-Dr. Concha GilMadrid Science Park-Computensis University (PCM-UCM), ProteoRed, MadridRU2e-Dr. Manuel Sanchez del PinoFelipe Princess Research Center (CIPF), ProteoRed, ValenciaRU2f-Dr. Fernando Vivanco / Dr. ME BarderasJimenez Díaz Foundation (FJD), Madrid /National Paraplegics Hospital, ToledoRU2g-Dr. Francisco BlancoInstituto de Investigacion Biomedica (INIBIC), ProteoRed, La CoruñaRU2h-Dr Silvia BarcelóAragón Health Sciences Institute (IACS), Zaragoza
WG1-Protein Micro Array & Peptide Standard TeamRU1a (Peptide standardization Team):Dr. Manuel FuentesCentro de Investigación del Cáncer/IBMCC (USAL/CSIC), SalamancaRU1b (Protein Micro Array and Protein expression Team): Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid
WG1-Protein Micro Array & Peptide Standard TeamRU1a (Peptide standardization Team):Dr. Manuel FuentesCentro de Investigación del Cáncer/IBMCC (USAL/CSIC), SalamancaRU1b (Protein Micro Array and Protein expression Team): Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid
WG3-Protein Sequencing Team RU3a-Dr. José M. Mato / Dr. Félix ElortzaCIC-BioGUNE, ProteoRed, BilbaoRU3b-Dr. Joaquin AbianIIBB, CSIC ProteoRed, BarcelonaRU3c-Dr. Manuel Sanchez del PinoUniversity of Valencia, ProteoRed, ValenciaRU3d-Dr. Eliandre de OliveiraParc Científic de Barcelona (PCB), ProteoRed, BarcelonaRU3e-Dr. Ignacio CasalBiology Research Center-CSIC (CIB-CSIC), ProteoRed, MadridRU3f-Dr. Jesus M. ArizmendiBasque Country University ProteoRed, BilbaoRU3g-Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid
WG3-Protein Sequencing Team RU3a-Dr. José M. Mato / Dr. Félix ElortzaCIC-BioGUNE, ProteoRed, BilbaoRU3b-Dr. Joaquin AbianIIBB, CSIC ProteoRed, BarcelonaRU3c-Dr. Manuel Sanchez del PinoUniversity of Valencia, ProteoRed, ValenciaRU3d-Dr. Eliandre de OliveiraParc Científic de Barcelona (PCB), ProteoRed, BarcelonaRU3e-Dr. Ignacio CasalBiology Research Center-CSIC (CIB-CSIC), ProteoRed, MadridRU3f-Dr. Jesus M. ArizmendiBasque Country University ProteoRed, BilbaoRU3g-Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid
Aims to achieve in the 1st Chr-16 Consortium Meeting
• Evaluation of the strategy defined in the April 2nd S_HPP Meeting: S/MRM, AIMS, Shotgun, cell culture, protein expression, data base, bioinformatics platform, data workflow
• Preparation of JPR manuscript, HUPO-Boston Posters…
• 2012 Working plan (short and medium term)
HUPO CONGRESS POSTERS (I)
• RE: Abstract log #322 Your abstract entitled Chromosome 16 Consortium: Current Developments on the Characterization of the Proteins Encoded by the Chromosome 16" (log #322) is formally accepted for poster presentation at the HUPO 11th Annual World Congress, September 9-13, 2012 in Boston, MA (USA).
• RE: Abstract log #146 Your abstract entitled Chromosome 16. Transcriptomic profiling of lymphocyte B Ramos cells, MCF-7 epithelial cells and CCD18 fibroblasts (log #146) is formally accepted for poster presentation at the HUPO 11th Annual World Congress, September 9-13, 2012 in Boston, MA (USA).
• RE: Abstract log #368 Your abstract entitled Profiling the Chromosome 16 by high-resolution data-dependent Mass Spectrometry (log #368) is formally accepted for poster presentation at the HUPO 11th Annual World Congress, September 9-13, 2012 in Boston, MA (USA).
•
HUPO CONGRESS POSTERS (II)
• RE: Your abstract log# 758 for the HUPO2012 conference was submitted on 6/30/2012.The log number for your abstract is 758. Chromosome 16 Consortium: The Spanish B/D-C-HPP Initiative Juan P Albar; Jesus Fortun; Jesus Mari Arizmendi; Cristobal Belda; Ignacio Casal; Fernando Corrales; Concha Gil; Adolfo Lopez-Munain; Jesus Prieto; Jesus Rodriguez-Padial; Fernando Vivanco; Francisco J Blanco . Spanish B/D-HPP Consortium, A Coruña, Spain.
•RE: Abstract log #217 Your abstract entitled Automatic reporting and reproducibility analysis of ProteoRed participants in the multi-laboratory studies using the “MIAPE extractor” tool (log #217) is formally accepted for poster presentation at the HUPO 11th Annual World Congress, September 9-13, 2012 in Boston, MA (USA).
• RE: Abstract log# 785 Your abstract entitled Reporting and connecting experimental information through proteomics data standards. J. Alberto Medina-Aunon; Salvador Martínez de Bartolomé; Miguel A. López; Juan P. Albar Centro Nacional de Biotecnología - CSIC, Madrid, Spain for the HUPO2012 conference was submitted on 7/11/2012.
Top Related